title: A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
authors: G
authors: G
authors: Ramsingh
authors: P
authors: P
authors: Westervelt
authors: A F
authors: AF
authors: Cashen
authors: G L
authors: GL
authors: Uy
authors: K
authors: K
authors: Stockerl-Goldstein
authors: C N
authors: CN
authors: Abboud
authors: N
authors: N
authors: Bernabe
authors: R
authors: R
authors: Monahan
authors: J F
authors: JF
authors: DiPersio
authors: R
authors: R
authors: Vij
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D055815:Young Adult
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine